I keep a nerdy spreadsheet of trial readouts, mostly to guess what might come next for people like me. The tirzepatide + eloralintide combo is the first thing that has made me second-guess retatrutide’s spot at the top of my mental leaderboard.
In the trials, the combo’s weight-loss curves look steeper at similar timepoints, and the amylin piece seems to add satiety without the same GI tax on paper.
But cross-trial comparisons are shaky: different populations, titration schedules, and durations. I’m not changing anything based on a poster. Personal data point: 14 months on tirzepatide, 61 lb down, but my loss has flattened around 183 for six weeks, and my waist tape hasn’t moved either.
That plateau is why the combo data has my attention. For folks who read the actual papers instead of headline charts, what are you watching — lean mass, GI tolerability, or dropout curves?